Massmutual Trust Co. FSB ADV raised its stake in Abbott Laboratories (NYSE:ABT – Free Report) by 2.1% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 67,299 shares of the healthcare product maker’s stock after purchasing an additional 1,379 shares during the quarter. Massmutual Trust Co. FSB ADV’s holdings in Abbott Laboratories were worth $7,673,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors also recently modified their holdings of ABT. Vanguard Group Inc. grew its stake in shares of Abbott Laboratories by 5.6% in the 1st quarter. Vanguard Group Inc. now owns 165,301,921 shares of the healthcare product maker’s stock valued at $18,788,216,000 after purchasing an additional 8,834,840 shares during the last quarter. Capital International Investors lifted its holdings in shares of Abbott Laboratories by 9.1% in the 1st quarter. Capital International Investors now owns 70,177,564 shares of the healthcare product maker’s stock valued at $7,976,382,000 after buying an additional 5,882,780 shares during the period. Swedbank AB acquired a new stake in shares of Abbott Laboratories in the 1st quarter valued at approximately $341,777,000. Sessa Capital IM L.P. acquired a new stake in shares of Abbott Laboratories in the 2nd quarter valued at approximately $264,876,000. Finally, Assenagon Asset Management S.A. lifted its holdings in shares of Abbott Laboratories by 493.1% in the 2nd quarter. Assenagon Asset Management S.A. now owns 2,401,190 shares of the healthcare product maker’s stock valued at $249,508,000 after buying an additional 1,996,320 shares during the period. 75.18% of the stock is currently owned by hedge funds and other institutional investors.
Insider Buying and Selling
In related news, CEO Robert B. Ford sold 141,679 shares of the business’s stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $116.41, for a total value of $16,492,852.39. Following the transaction, the chief executive officer now owns 220,059 shares in the company, valued at $25,617,068.19. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 1.10% of the company’s stock.
Wall Street Analyst Weigh In
View Our Latest Stock Report on Abbott Laboratories
Abbott Laboratories Price Performance
ABT stock opened at $113.64 on Thursday. The stock has a 50-day moving average price of $112.10 and a two-hundred day moving average price of $108.19. Abbott Laboratories has a 12-month low of $89.67 and a 12-month high of $121.64. The company has a current ratio of 1.68, a quick ratio of 1.18 and a debt-to-equity ratio of 0.33. The company has a market cap of $197.69 billion, a PE ratio of 35.40, a price-to-earnings-growth ratio of 2.86 and a beta of 0.72.
Abbott Laboratories (NYSE:ABT – Get Free Report) last issued its quarterly earnings data on Thursday, July 18th. The healthcare product maker reported $1.14 EPS for the quarter, topping analysts’ consensus estimates of $1.10 by $0.04. The company had revenue of $10.38 billion for the quarter, compared to analysts’ expectations of $10.37 billion. Abbott Laboratories had a return on equity of 20.18% and a net margin of 13.65%. The firm’s quarterly revenue was up 4.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.08 earnings per share. As a group, research analysts predict that Abbott Laboratories will post 4.66 EPS for the current year.
Abbott Laboratories Announces Dividend
The firm also recently declared a quarterly dividend, which will be paid on Friday, November 15th. Investors of record on Tuesday, October 15th will be paid a $0.55 dividend. This represents a $2.20 annualized dividend and a dividend yield of 1.94%. The ex-dividend date of this dividend is Tuesday, October 15th. Abbott Laboratories’s dividend payout ratio (DPR) is 68.54%.
Abbott Laboratories Company Profile
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.
Featured Articles
- Five stocks we like better than Abbott Laboratories
- 3 Warren Buffett Stocks to Buy Now
- Harness the Power of Dividend ETFs for Steady Income Growth
- What is the Shanghai Stock Exchange Composite Index?
- Energy Sector Rebound: 3 Stocks Poised for Strong Gains
- Differences Between Momentum Investing and Long Term Investing
- Maximize Your Returns: 3 Dividend Stocks With Yields Over 5%
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.